Semaglutide News and Research

Latest Semaglutide News and Research

FDA issues complete response letter for BYDUREON NDA

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for BYDUREON™ (exenatide extended-release for injectable suspension).

21 Oct 2010

Particle Sciences enters licensing, technology agreement with Solubest

Particle Sciences Inc. (PSI), a leading pharmaceutical CRO and SoluBest have entered into a licensing and technology development agreement. Under the agreement, Particle Sciences will be the exclusive contract research provider in the U.S. for SoluBest's Solumer technology.

20 Oct 2010

Accium announces new pricing for AMS measurement service

Accium BioSciences, a leading provider of bioanalytical accelerator mass spectrometry (AMS) services in North America, announced today new pricing for its AMS measurement service at $99 per sample. GLP-compliant service is now available at $115 per sample. The new pricing includes sample graphitization and AMS measurement services.

19 Oct 2010

Beta-Pro expands operations to meet increasing demand in $2 billion hepatocyte market

Beta-Pro LLC, announced today that it has expanded its operations to accommodate increasing demands from pharmaceutical drug discovery and research institutes in the $2 billion hepatocyte market. The human cellular sciences company now manages extensive laboratory facilities in the University of Virginia Research Park in Charlottesville, Virginia.

13 Oct 2010

Helix completes GLP toxicology study milestone in L-DOS47 development program

Helix BioPharma Corp. today announced that it has completed its definitive GLP, rodent and primate, repeat-dose toxicology studies with L-DOS47. These studies demonstrated a good safety profile in an expanded number of rodent and primate test animals, building upon Helix's positive findings from its preliminary non-GLP toxicology studies.

12 Oct 2010

Exelixis enters two new collaboration agreements with Bristol-Myers Squibb

Exelixis, Inc. announced today that it has entered into two new collaboration agreements with Bristol-Myers Squibb Company. Under the first agreement, Exelixis will grant to Bristol-Myers Squibb an exclusive license to its small-molecule TGR5 agonist program including backups.

11 Oct 2010

Australian reimbursement committee is set to consider Novo Nordisk's type 2 diabetes treatment

In its November meeting, the Pharmaceutical Benefits Advisory Committee (PBAC) will consider Novo Nordisk's second-to-market glucagon-like peptide-1 (GLP-1) agonist Victoza for reimbursement, which would be essential in order for the drug to compete effectively with Eli Lilly's Byetta. However, its chances of success are uncertain, considering that it took three years to get Byetta on the Pharmaceutical Benefits Scheme (PBS).

4 Oct 2010

sanofi-aventis announces top-line results from lixisenatide Phase III GETGOAL-L-ASIA trial for Type-2 Diabetes

Zealand Pharma A/S, the biopharmaceutical company dedicated to the discovery and development of innovative peptide-based drugs, is pleased to note that its partner, sanofi-aventis, has today announced positive top-line results of the Phase III GETGOAL-L-ASIA trial which assessed the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist discovered by Zealand Pharma, in combination with basal insulin.

30 Sep 2010

Beta-Pro donates human pancreatic islet cells to diabetes researcher

The cellular services company Beta-Pro LLC, announced today that it donated more than 300,000 human pancreatic islet cells to nationally renowned diabetes researcher Raghavendra G. Mirmira, M.D., Ph.D., the Eli Lilly & Co. Professor of Pediatric Diabetes, Indiana University School of Medicine, Herman B.

23 Sep 2010

Intarcia Therapeutics presents ITCA 650 phase 2 study results for type 2 diabetes

Intarcia Therapeutics, Inc. presented today final results of a 24-week phase 2 clinical study of ITCA 650 (DUROS continuous subcutaneous delivery of exenatide) for the treatment of type 2 diabetes at the 46th Annual Meeting of the European Association for the Study of Diabetes in Stockholm, Sweden.

23 Sep 2010

Lixisenatide experimental diabetes drug shows potential in trial

Researchers at the R&D section of drug maker Sanofi Aventis have confirmed this Monday that a study of its experimental diabetes drug showed better blood sugar control than placebo.

21 Sep 2010

Phase III trial results of lixisenatide for type 2 diabetes presented at 46th EASD

Sanofi-aventis announced today the first Phase III results of the GetGoal clinical trial program assessing the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist, as monotherapy in patients with type 2 diabetes. These results were presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting in Stockholm, Sweden.

20 Sep 2010

Emisphere’s SNAC drug successful in reducing food intake; increasing satiety

Emisphere Technologies, Inc. today announced that a clinical study found that the company's proprietary oral SNAC (Sodium N-[8-(2-hydroxybenzoyl) Amino] Caprylate ("SNAC") additive, in combination with two digestive hormones, was successful in reducing food intake and increasing satiety in healthy male subjects.

18 Sep 2010

Transition stops TT-223 gastrin analogue combination clinical study in type 2 diabetes

Transition Therapeutics Inc. announced today that a clinical study of gastrin analogue TT-223 in combination with a Lilly proprietary GLP-1 analogue in patients with type 2 diabetes did not meet its efficacy endpoints. Given these findings, there will be no further development of TT-223.

17 Sep 2010

TransPharma Medical completes ViaDerm-GLP1 agonist Phase 1a trial for type II diabetes

TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today the successful completion of a Phase 1a trial of ViaDerm-GLP1 agonist which is being developed for the treatment of diabetes mellitus type II.

14 Sep 2010

Cetero Research expands Clinical Dermatology and Transdermal Delivery System services

Cetero Research, the leading early stage contract research organization (CRO), today announced the expansion of multiple Clinical Dermatology and Transdermal Delivery System (TDDS) services to four Cetero clinical facilities.

20 Aug 2010

NIEHS procures Provantis preclinical software solution for National Toxicology Program studies

Instem, a leading provider of early drug development software solutions, announced today that the National Institute of Environmental Health Sciences has purchased the Provantis® preclinical software solution to support the collection, management and maintenance of the reproductive, perinatal and developmental National Toxicology Program studies. These studies are done predominantly at contractor laboratories at various sites throughout the United States.

13 Aug 2010

Evotec revenues for first-half of 2010 increase 33% to € 25.0 m

Evotec AG today reported financial results and corporate updates for the first half of 2010.

12 Aug 2010

Lexicon Pharmaceuticals updates key progress in clinical pipeline

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated the progress of its drug development programs and reported financial results for the three and six months ended June 30, 2010.

9 Aug 2010

Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million

Repligen Corporation today reported results for the first quarter of fiscal year 2011, ended June 30, 2010. Total revenue for the first quarter was $7,010,000 compared to total revenue of $5,061,000 for the first quarter of fiscal year 2010, an increase of $1,949,000 or 39%. Bioprocessing product revenue for the first quarter was $4,269,000 compared to $2,473,000 for the first quarter of fiscal 2010, an increase of $1,796,000 or 73%.

5 Aug 2010

Semaglutide News and Research

Latest Semaglutide News and Research

FDA issues complete response letter for BYDUREON NDA

Particle Sciences enters licensing, technology agreement with Solubest

Accium announces new pricing for AMS measurement service

Beta-Pro expands operations to meet increasing demand in $2 billion hepatocyte market

Helix completes GLP toxicology study milestone in L-DOS47 development program

Exelixis enters two new collaboration agreements with Bristol-Myers Squibb

Australian reimbursement committee is set to consider Novo Nordisk's type 2 diabetes treatment

sanofi-aventis announces top-line results from lixisenatide Phase III GETGOAL-L-ASIA trial for Type-2 Diabetes

Beta-Pro donates human pancreatic islet cells to diabetes researcher

Intarcia Therapeutics presents ITCA 650 phase 2 study results for type 2 diabetes

Lixisenatide experimental diabetes drug shows potential in trial

Phase III trial results of lixisenatide for type 2 diabetes presented at 46th EASD

Emisphere’s SNAC drug successful in reducing food intake; increasing satiety

Transition stops TT-223 gastrin analogue combination clinical study in type 2 diabetes

TransPharma Medical completes ViaDerm-GLP1 agonist Phase 1a trial for type II diabetes

Cetero Research expands Clinical Dermatology and Transdermal Delivery System services

NIEHS procures Provantis preclinical software solution for National Toxicology Program studies

Evotec revenues for first-half of 2010 increase 33% to € 25.0 m

Lexicon Pharmaceuticals updates key progress in clinical pipeline

Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Semaglutide News and Research

Latest Semaglutide News and Research

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in